000 01301 a2200373 4500
005 20250514055936.0
264 0 _c20030416
008 200304s 0 0 eng d
022 _a0269-2813
024 7 _a10.1046/j.1365-2036.2003.01445.x
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aBrunner, M
245 0 0 _aGastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation.
_h[electronic resource]
260 _bAlimentary pharmacology & therapeutics
_cFeb 2003
300 _a395-402 p.
_bdigital
500 _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article
650 0 4 _aAdult
650 0 4 _aDelayed-Action Preparations
650 0 4 _aGastrointestinal Transit
_xphysiology
650 0 4 _aHumans
650 0 4 _aIntestinal Absorption
_xphysiology
650 0 4 _aMale
650 0 4 _aMesalamine
_xadministration & dosage
650 0 4 _aTablets
700 1 _aAssandri, R
700 1 _aKletter, K
700 1 _aTschurlovits, M
700 1 _aCorrado, M E
700 1 _aVilla, R
700 1 _aEichler, H G
700 1 _aMüller, M
773 0 _tAlimentary pharmacology & therapeutics
_gvol. 17
_gno. 3
_gp. 395-402
856 4 0 _uhttps://doi.org/10.1046/j.1365-2036.2003.01445.x
_zAvailable from publisher's website
999 _c12361383
_d12361383